December 7, 2018
Chugai Pharmaceutical said on December 6 that its anti-PD-L1 antibody Tecentriq (atezolizumab) earned orphan drug designation in Japan for the treatment of small cell lung cancer (SCLC). In Japan, Chugai is running seven lung cancer trials for Tecentriq, including the...read more